Showing 5641-5650 of 5956 results for "".
- EU-5 Ophthalmic Market Will Top $10 Billion in 2023https://modernod.com/news/eu-5-ophthalmic-market-will-top-10-billion-in-2023/2476311/Market Scope expects growing demand for retinal pharmaceuticals to help manufacturers’ ophthalmic revenues top $10 billion in 2023 in the five largest economies of the European Union. The ophthalmic markets in France, Germany, Italy, Spain, and the UK––the five countries that made up
- Regeneron Q4 Earnings & Sales Beat on Strong Eylea Saleshttps://modernod.com/news/regeneron-q4-earnings-sales-beat-on-strong-eylea-sales/2476314/Regeneron Pharmaceuticals delivered impressive results in the fourth quarter of 2018 wherein both earnings and sales beat estimates, according to a Nasdaq report. Shares ar
- Laser Vision Correction Market Growth Continues for Third Consecutive Yearhttps://modernod.com/news/laser-vision-correction-market-growth-continues-for-third-consecutive-year/2476315/US laser vision correction procedure volume grew for the third straight year in 2018, reflecting continued strong demand for LASIK and other forms of laser vision correction, according to figures released by The Refra
- Graybug Vision Appoints Frédéric Guerard as Chief Executive Officerhttps://modernod.com/news/graybug-vision-appoints-frederic-guerard-as-chief-executive-officer/2476318/Graybug Vision announced that the board of directors has appointed Frédéric Guerard as Chief Executive Officer. Mr. Guerard’s career in the pharmaceutical industry spans over 20 years and includes multiple leadership, strategic, and commercial roles. He joins from Novartis, where he was pr
- Eye Movements May Flag Cognitive Impairment in Schizophreniahttps://modernod.com/news/eye-movements-may-flag-cognitive-impairment-in-schizophrenia/2476319/Eye-movement abnormalities may flag specific types of cognitive impairment in schizophrenia patients, new research shows, according to a Medscape report. A multicenter study found that scanpath length and matrix reasoning were more
- Galimedix Therapeutics Presents Data for Investigational Eyedrops Containing GAL-101https://modernod.com/news/galimedix-therapeutics-presents-data-for-investigational-eyedrops-containing-gal-101/2476320/Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, presented an overview of data disclosed to date on its novel, first-in-class, investigational compound GAL-101, which in animal models caused sustained prevention of misfolded amyloid beta mol
- Harrow Health Announces $11 Million Series A Financing for Melt Pharmaceuticals Subsidiaryhttps://modernod.com/news/harrow-health-announces-11-million-series-a-financing-for-melt-pharmaceuticals-subsidiary/2476323/Melt Pharmaceuticals, an affiliated company of Harrow Health, announced it has entered into definitive stock purchase agreements with accredited and institutional investors to raise proceeds of approximately $11 million in a private placement sale of its Series A preferred stock at $5 per share.
- CorneaGen to Acquire KeraLink Domestic Eye Bank Operationshttps://modernod.com/news/corneagen-to-acquire-keralink-domestic-eye-bank-operations/2476326/CorneaGen and KeraLink International, a provider of corneal transplantation services, supplies and grafts for transplant, have signed a final agreement for CorneaGen to acquire KeraLink’s domestic eye bank operations and related assets. Financial terms of the deal were not disclosed. <
- SECO International Names J. Max Ernst, OD, as 2020 Presidenthttps://modernod.com/news/seco-international-names-j-max-ernst-od-as-2020-president/2476329/SECO International, the world’s largest educational conference, has announced that J. Max Ernst, OD, will become the next SECO International President. Dr. Ernst will officially accept the honor during the House of Delegates meeting, held during SECO 2019, Saturday, February 23, from 3:15 pm-5 pm
- New US Experiments Aim To Create Gene-Edited Human Embryoshttps://modernod.com/news/new-us-experiments-aim-to-create-gene-edited-human-embryos/2476330/A scientist in New York is conducting experiments designed to modify DNA in human embryos as a step toward someday preventing inherited diseases, according to an NPR